Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Should You Sell?

Shares of Sysmex Corporation ADR (OTCMKTS:SSMXY) gapped down before the market opened on Wednesday . The stock had previously closed at $8.50, but opened at $8.16. Sysmex shares last traded at $8.53, with a volume of 1,667 shares traded.

Wall Street Analyst Weigh In

Separately, Citigroup downgraded Sysmex from a “strong-buy” rating to a “hold” rating in a report on Monday, March 16th. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold”.

Sysmex Stock Performance

The stock has a market capitalization of $5.36 billion, a PE ratio of 17.72 and a beta of 1.14. The company has a quick ratio of 2.44, a current ratio of 3.33 and a debt-to-equity ratio of 0.12. The firm has a 50 day moving average price of $9.20 and a 200-day moving average price of $10.31.

Sysmex (OTCMKTS:SSMXY) last announced its quarterly earnings data on Thursday, February 12th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.14 by $0.01. The business had revenue of $837.32 million during the quarter, compared to analysts’ expectations of $819.99 million. Sysmex had a net margin of 8.86% and a return on equity of 9.27%. Research analysts expect that Sysmex Corporation ADR will post 0.57 EPS for the current fiscal year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.